Empagliflozin in Patients with Chronic Kidney Disease
Open accessThe DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index; 19 of the 28 sources its claims cite were checked for support.
Abstract
Trial of empagliflozin in a broad chronic kidney disease population.
Overview
CoChat Summary
TL;DR
Empagliflozin 10 mg daily reduced the risk of the composite of kidney disease progression or cardiovascular death in the EMPA-KIDNEY randomized trial of 6609 people with chronic kidney disease. Benefits were consistent with and without diabetes and across the eGFR range studied, with no clear increase in serious adverse events overall.
Key findings
- The primary composite outcome occurred in 432 of 3304 patients (13.1%) on empagliflozin versus 558 of 3305 (16.9%) on placebo; hazard ratio 0.72 (95% CI 0.64 to 0.82; P<0.001).
- All-cause hospitalizations were fewer with empagliflozin: 24.8 versus 29.2 hospitalizations per 100 patient-years; hazard ratio 0.86 (95% CI 0.78 to 0.95; P=0.003).
- There was no statistically significant effect on hospitalization for heart failure or cardiovascular death (4.0% vs 4.6%; hazard ratio 0.84, 95% CI 0.67 to 1.07; P=0.15) or death from any cause (4.5% vs 5.1%; hazard ratio 0.87, 95% CI 0.70 to 1.08; P=0.21).
- Empagliflozin slowed eGFR decline: the between-group difference in chronic slope was 1.37 ml/min/1.73 m² per year (95% CI 1.16 to 1.59), and urinary ACR was reduced by 19% (95% CI 15% to 23%).
Methods
- Multicenter, international, randomized, double-blind, placebo-controlled trial conducted at 241 centers in 8 countries; 6609 participants were randomized to empagliflozin 10 mg once daily or matching placebo.
- Eligible adults had CKD with eGFR ≥20 to <45 ml/min/1.73 m², or eGFR ≥45 to <90 ml/min/1.73 m² with urinary ACR ≥200 mg/g; patients with or without diabetes were eligible, and those with polycystic kidney disease or a kidney transplant were excluded.
- Primary analysis used intention-to-treat Cox regression adjusted for age, sex, prior diabetes, eGFR, urinary ACR, and region; key secondary outcomes were multiplicity-adjusted, and eGFR slope was assessed with shared parameter models.
Limitations
- The paper states that the lower-than-expected cardiovascular event rate reduced statistical power for secondary or tertiary cardiovascular outcomes.
- Evident from the text: the trial was stopped early for efficacy at an interim analysis, so follow-up was relatively short (median 2.0 years).
- Evident from the text: some subgroup estimates, especially for lower albuminuria strata, were limited by fewer primary outcome events.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
10 Valid · 0 Not valid · 4 Not checked · 40 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A prespecified subgroup analysis from a trial of the SGLT2 inhibitor dapagliflozin in patients with CKD and a urinary ACR of at least 200 mg/g, found that kidney benefits extended to patients without diabetes”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Conclusions
What the sources say
- Supportedcites [7] Heerspink HJL Stefansson BV Correa-Rotter R Dapagliflozin in Patients with Chronic Kidney Disease N Engl J Med 2020 383 15 1436 1446 10.1056/NEJMoa2024816 32970396 source
The Abstract (p. 1437) specifies a urinary albumin-to-creatinine ratio of 200–5000 mg/g. Figure 2 identifies diabetes status as a prespecified subgroup, and the Discussion states that kidney-protective effects extended to participants with chronic kidney disease without type 2 diabetes. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [12] Wheeler DC Stefansson BV Jongs N Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial Lancet Diabetes Endocrinol 2021 9 1 22 31 10.1016/S2213-8587(20)30369-7 33338413 source
- Supportedcites [13] Staplin N Roddick AJ Emberson J Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials EClinicalMedicine 2021 41 101163 10.1016/j.eclinm.2021.101163 34765951 PMC8571171 source
The Results (Eligible trial characteristics) identify DAPA-CKD as a dapagliflozin trial in patients with CKD and urinary ACR of 200–5000 mg/g. The Results (Relative effects of SGLT-2 inhibitors) report that the effect on kidney disease progression in the CKD trial appeared similar with and without diabetes; the References identify the underlying DAPA-CKD work as a prespecified analysis. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The effect of SGLT2 inhibition on kidney disease progression or cardiovascular death seen in the present trial is quantitatively similar to that seen in two other large placebo-controlled trials in CKD populations.6,7”
§ Empagliflozin in Patients with Chronic Kidney Disease > Discussion
What the sources say
- Supportedcites [6] Perkovic V Jardine MJ Neal B Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy N Engl J Med 2019 380 24 2295 2306 10.1056/NEJMoa1811744 30990260 source
The Methods identify CREDENCE as a placebo-controlled trial in patients with type 2 diabetes and albuminuric CKD. Table 2 reports a hazard ratio of 0.70 for its primary composite of kidney disease progression or renal or cardiovascular death. This supports the citation’s role as one of the two earlier CKD trials; the paper does not itself compare its result with EMPA-KIDNEY. (LLM, conf=0.88)
- Supportedcites [7] Heerspink HJL Stefansson BV Correa-Rotter R Dapagliflozin in Patients with Chronic Kidney Disease N Engl J Med 2020 383 15 1436 1446 10.1056/NEJMoa2024816 32970396 source
The Efficacy Outcomes table reports that DAPA-CKD was a placebo-controlled trial in patients with chronic kidney disease and found a lower risk of the kidney-progression or cardiovascular-death composite with dapagliflozin (hazard ratio, 0.61). The cited paper supplies one of the two trial results; the statement that its effect is quantitatively similar to EMPA-KIDNEY is the citing authors’ comparison, not a finding attributed to this paper alone. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“or death from any cause (4.5% vs 5.1%)”
- Also stated in: § Primary and Secondary Outcomes · plain
“or on death from any cause (hazard ratio, 0.87; 95% CI 0.70 to 1.08; P=0.21)”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Primary and Secondary Outcomes · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The rates of serious adverse events were broadly similar in the two groups.”
- Also stated in: § Safety Outcomes and Adverse Events · hedged
“There was no apparent evidence that empagliflozin increased the incidence of serious adverse events overall, or in any particular MedDRA system organ class (Table S8).”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Safety Outcomes and Adverse Events · hedged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were fewer hospitalizations from any cause in the empagliflozin group (0.86; 0.78 to 0.95, P=0.003)”
- Also stated in: § Primary and Secondary Outcomes · plain
“there were significantly fewer first and subsequent hospitalizations from any cause in the empagliflozin group (24.8 versus 29.2 hospitalizations per 100 patient years: hazard ratio, 0.86; 95% CI 0.78 to 0.95, P=0.003)”
- Also stated in: § Discussion · plain
“Risk of hospitalization for any cause was also reduced by 14%.”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Primary and Secondary Outcomes · plain
17 more claims
Create a free account to see all 54 claims and every source verdict.
- It may state two separate claims as one. 24
- Probably not a substantial claim. 16
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The empagliflozintreated participants had lower risk of progression of kidney disease and lower risk of death from cardiovascular causes (HR 0.72 [95% CI 0.64-0.82];P < 0.001).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [115]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The empagliflozin-treated participants had lower risk of progression of kidney disease and lower risk of death from cardiovascular causes (HR 0.72 [95% CI 0.64-0.82];P < 0.001).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [128]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Dedicated kidney outcomes trials in people with CKD and type 2 diabetes have shown that the SGLT2 inhibitors empagliflozin, canagliflozin, and dapagliflozin have beneficial effects on slowing progression of CKD and CV outcomes in this population (139-141).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [141]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, SGLT2i have been studied specifically among patients with CKD with or without T2D in 3 completed primary kidney outcome trials (CREDENCE[15], DAPA-CKD[16], and EMPA-KIDNEY[17]), which showed benefit for both a significant reduction in the primary kidney outcomes and cardiovascular outcomes [18,19].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“The DAPA-CKD and FIDELIO trials enrolled patients with eGFR ≥25 mL/min/1.73 m2 and the EMPA-KIDNEY trial enrolled patients with eGFR ≥20 mL/min/1.73 m2; results demonstrated that dapagliflozin, finerenone and empagliflozin are effective and safe in these patients, although safety data are lacking for initiating therapy below these thresholds [16,17,22].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [17]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493 · cited 1×
“…kidney disease with increased levels of albuminuria, large placebo-controlled trials have shown that renin-angiotensin system (RAS) inhibitors, 3–5 sodium-glucose cotransporter 2 (SGLT2) inhibitors, 6,7 and the non-steroidal mineralocorticoid receptor antagonist finerenone 8,9 all reduced the…”
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 2×
“6,7 The CREDENCE trial of canagliflozin required all participants to have type 2 diabetes and a urinary ACR of at least 300 mg/g, and excluded patients with an eGFR of less than 30 ml per minute per 1.73 m 2 .”
InfluentialLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618 · cited 3×
“…with an estimated GFR (eGFR) below 30 ml per minute per 1.73 m 2 or on how these benefits might vary among the wider range of patients with CKD. 7,12,13 This multicenter international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess…”
InfluentialThe effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Cited by
Items 2,001–2,100 of 2,656
Osanami, A., Komatsu, H., Gocho, Y., Nishizawa, K., Tanaka, M., Nakamura, Y., & Furuhashi, M. (2025) · Clinical and Experimental Nephrology · doi:10.1007/s10157-025-02625-8
“Recently, clinical trials have shown that sodium glucose cotransporter 2 (SGLT2) inhibitors improve renal outcomes in both CKD patients with and those without diabetes mellitus [7, 8].”
Chronic Kidney Disease in Balkan Countries—A Call for Optimal Multidisciplinary Management
Laganović, M., Naumovic, R. T., Nikolova, M., Petrov, P., Radić, J., Mitić, I. M., & Pernat, A. M. (2025) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph22020140 · Cited by 1
Bewährtes und Neues in der Therapie der Herzinsuffizienz
Schwenger, V. (2025) · Die Nephrologie · doi:10.1007/s11560-024-00821-3
McEvoy, J. W., McCarthy, C. P., Brouwers, S., & Others, A. (2025) · HYPERTENSION · doi:10.22141/2224-1485.17.4.2024.372 · Cited by 2
Clinical Trials Show Promise for Novel Treatments for IgA Nephropathy
Bose, B. (2025) · Kidney News · doi:10.62716/kn.000452024
Advancements in the Research of Non-Immunosuppressive Therapies for Chronic Kidney Disease
王, 欣. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.151288
Vijayan, A., Lanzinger, S., Forestier, N., Hess, G., Rottmann, M., Wosch, F. J., Seufert, J., Holl, R. W., Bramlage, P., & for the, D. P. V. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16245
Aktueller Stand der Nephroprotektion in der Diabetologie
Schmieder, R. E., & Striepe, K. (2025) · Journal für Endokrinologie Diabetologie und Stoffwechsel · doi:10.1007/s41969-025-00258-6
Mitigating heart failure risk in patients with diabetes and chronic kidney disease
Kowalczyk, N. S., & Prochaska, M. (2025) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001208
Non-linear association between AKI alert detection rate by physicians and medical costs
Ai, H.-J., Jiang, E.-L., Wang, H., Yang, Q., Jin, Q., Wan, L., Liu, J., & He, C. (2025) · PLoS ONE · doi:10.1371/journal.pone.0314907 · Cited by 1
Sind GLP-1-Rezeptor-Agonisten und SGLT2-Inhibitoren auch im höheren Lebensalter geeignet?
Stüdemann, S., & Engeli, S. (2025) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2492-9440
Liu, J., & Xu, J. (2025) · Rheumatology & autoimmunity · doi:10.1002/rai2.12172
IgA Nephropathy and Glomerular Diseases Associated with Infection
Gleeson, P. J., & Barratt, J. (2025) · Nephrology Self-Assessment Program · doi:10.58483/nsap.00012025
Diabetes mellitus and chronic renal insufficiency
Girman, P. (2025) · Vnitřní lékařství · doi:10.36290/vnl.2025.018
Liang, R.-S., Su, J. Q., Wu, X., Wang, Q., Cai, Y.-M., Su, H.-Y., Tang, J., & Yao, C. (2025) · Scientific Reports · doi:10.1038/s41598-025-94761-0 · Cited by 3
Rungkitwattanakul, D. “., Evans, E. I., Brown, E., Patterson, K., Jr., Chaijamorn, W., Charoensareerat, T., Belrhiti, S., Nwaogwugwu, U., & Mere, C. (2025) · Pharmacy · doi:10.3390/pharmacy13020052
Treatment Progress of SGLT2 Inhibitors in Anemia of CKD
张, 润. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.154981
Hypertension in Acute Kidney Injury
Vellanki, K., & Griffin, K. A. (2025) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-031-81292-7_2
Kidney disease in patients with HIV
Mejia, S. M., Fischman, C. J., & Sise, M. E. (2025) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000941 · Cited by 1
Treatment of Hypertension in Chronic Kidney Disease
Redón, J. (2025) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-031-81292-7_15
Kraft, L., Latus, J., & Schanz, M. (2025) · Die Nephrologie · doi:10.1007/s11560-025-00844-4
Ena, J., Carretero‐Gómez, J., Tembra, M. S., Villar, L. L., Pena, C., Rosales‐Castillo, A., Pinilla, N. D., Carrasco-Sánchez, F. J., Merlo, A. B., Soler, A. R., et al. (2025) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2025.102279 · Cited by 1
Spencer, S., & Bhandari, S. (2025) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000001076 · Cited by 1
Ena, J., Carretero‐Gómez, J., Tembra, M. S., Villar, L. L., Peña, C. F., Rosales‐Castillo, A., Domínguez‐Pinilla, N., Carrasco-Sánchez, F. J., Bustos-Merlo, A., & Soler, A. (2025) · Revista Clínica Española · doi:10.1016/j.rce.2025.01.003 · Cited by 2
涂, 秋. (2025) · Journal of Clinical Personalized Medicine · doi:10.12677/jcpm.2025.42275
Gomes, J. N. D. A., Campos, M. D. S. B., Aragão, C. A. S., & Sousa, A. C. (2025) · ABC Heart Failure & Cardiomyopathy · doi:10.36660/abchf.20240032
SGLT2 inhibitors: towards a personalized prescription
de Fréminville, J.-B., & Bejan‐Angoulvant, T. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf220
Short-term prognostic score for very elderly patients, aged 85 or older, initiating hemodialysis
Mori, D., Hayashi, M., Honda, R., Tanoue, H., Kobayashi, M., Shimada, M., Tamai, S., Nomi, H., Nagatoya, K., & Yamauchi, A. (2025) · Journal of Nephrology · doi:10.1007/s40620-025-02292-8
Hong, D., Hong, M., Kim, O., Shin, H.-Y., Bak, M., Kim, D., Kim, J., Choi, K. H., Kim, E. K., Lee, J. M., et al. (2025) · Revista Española de Cardiología · doi:10.1016/j.recesp.2025.02.011 · Cited by 2
Vergallo, R., & Patrono, C. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf237
Gobbo, M. O. D. S., Sudo, R. Y. U., Milbradt, T. L., Reinheimer, I. C., Min, M., & Poli‐de‐Figueiredo, C. E. (2025) · Cureus · doi:10.7759/cureus.82458 · Cited by 1
“Despite the benefits in renal function and long-term albuminuria observed with other gliflozins, such as canagliflozin, dapagliflozin, and empagliflozin [20-23], the effects of bexagliflozin on renal outcomes remain uncertain.”
Valladares, P. G., Carrillo, M. D. J. S. A., Pérez, D. U., Quezada, O. I. O., & Mijangos, J. A. C. (2025) · Estudios y Perspectivas Revista Científica y Académica · doi:10.61384/r.c.a..v5i1.1086 · Cited by 1
Panagiotides, N. G., Weidenhammer, A., Prausmüller, S., Stadler, M., Spinka, G., Heitzinger, G., Arfsten, H., Strunk, G., Bartko, P. E., Goliasch, G., et al. (2025) · medRxiv · doi:10.1101/2025.04.21.25326175
Sodium-Glucose Transporter 2: Untangling the Mingled Yarn of Genetic and Pharmacologic Inhibition
Gulati, A. (2025) · Kidney360 · doi:10.34067/kid.0000000790 · Cited by 1
Bae, J. (2025) · Cardiovascular Prevention and Pharmacotherapy · doi:10.36011/cpp.2025.7.e4
Eine neue Ära der Diabetestherapie – Komorbiditäten im Fokus!
Lee-Barkey, Y. H., Arbi, A., Parizova, S., Danch, E., Willecke, F., Stratmann, B., & Tan, S. (2025) · Gefässchirurgie · doi:10.1007/s00772-025-01211-2
Buysschaert, M., Abodo, J., Belkhadir, J., & Buysschaert, B. (2025) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2025.04.004
Empagliflozin improves oxidative stress injury in the diabetic liver by regulating Nrf2 signaling
Zhang, X. (2025) · International Journal of Clinical and Experimental Medicine · doi:10.62347/ipjn8980
Merker, L., Ebert, T., Schleicher, E. D., et al. (2025) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2500-1124
“SGLT-2 inhibitors: The studies, which were specifically aimed at reducing renal endpoints, were able to impressively demonstrate the nephroprotective effect of canagliflozin, dapagliflozin and empagliflozin [15–17].”
I. Management of Kidney Disease Complicated with Heart Failure
Joki, N. (2024) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.113.766
Diagnosis and Therapy of Diabetes Based on Evidence
Shikata, K. (2025) · Health Evaluation and Promotion · doi:10.7143/jhep.52.370
Seikrit, C., & Mertens, P. R. (2025) · Elsevier eBooks · doi:10.1016/b978-3-437-21183-6.00004-0
Kraft, L., & Latus, J. (2025) · Elsevier eBooks · doi:10.1016/b978-3-437-21183-6.00003-9
Wolf, G., & Mertens, P. R. (2025) · Elsevier eBooks · doi:10.1016/b978-3-437-21183-6.00006-4
Navigating the CKM Conundrum: An Integrated Approach to Cardiovascular, Kidney, and Metabolic Health
Cross, L. V., Eichler, C., Jones, E. J., & Mcdaniel, L. (2025) · ADCES in Practice · doi:10.1177/2633559x251333384
Lachica, L. Á., & Garcia, M. (2023) · Actualización en Medicina de Familia · doi:10.55783/amf.190206
Nagasu, H., Nakashima, T., Ihara, K., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-6575802/v1
Kongestive Nephropathie – Ursachen, Diagnostik und Therapie
Wallbach, M., von Haehling, S., & Koziolek, M. J. (2025) · Die Innere Medizin · doi:10.1007/s00108-025-01894-5 · Cited by 2
Zhuravleva, M. V., Gagarina, J. V., & Marin, T. V. (2025) · Russian Journal of Cardiology · doi:10.15829/15604071-2025-6330
Lapsiwala, B. J., Nathani, P. S., Bhalodia, A. R., Rangan, A., Khan, F., Rajpopat, P. B., Vaghani, U., Kanagala, S. G., Bali, A., Naik, R., et al. (2025) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2025.05.004 · Cited by 1
Impact of medication assistance programs in pharmacist managed patients with diabetes
Cherry, M., & Cryder, B. T. (2025) · Discover Medicine · doi:10.1007/s44337-025-00359-w
Kao, Y., Chao, T., Cheng, Y., Chen, S., & Chan, Y. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70080 · Cited by 1
โรคไตจากเบาหวานประเภททไมมโปรตนรวทางปสสาวะ
ศรีสวัสดิ์, จ., & Satirapoj, B. (2025) · Journal of the Nephrology Society of Thailand · doi:10.63555/jnst.2025.277827
López, J. P., Capote, P. A. C., Pozo, A. H., Guerra, L. C., García, J. L., Olmo, R. F., & Huete, M. J. E. (2025) · Nefrología · doi:10.1016/j.nefro.2025.501359 · Cited by 1
Long-Term Effects of Empagliflozin in Chronic Kidney Disease
Yoshimoto, N., Azegami, T., & Hayashi, K. (2025) · New England Journal of Medicine · doi:10.1056/nejmc2504181
Malijan, G. M., Chapman, D., Moffat, S., Sardell, R. J., Staplin, N., Landray, M., Baigent, C., Shlipak, M. G., Haynes, R., Ix, J. H., et al. (2025) · medRxiv · doi:10.1101/2025.06.15.25329638
Cardiometabolic drugs and kidney function – a drug target Mendelian randomisation studyPreprint
Andries, A., Bennett, S. M., Walker, V. M., Heid, I. M., Köttgen, A., Gorski, M., Briasouli, A. A., Zheng, J., Hveem, K., Hallan, S. I., et al. (2025) · medRxiv · doi:10.1101/2025.06.16.25329403 · Cited by 1
Saeed, A., Younas, B., Rohan, A., Haider, U., Mukhtar, A., Nazir, M., & Maryam, M. (2025) · Cureus · doi:10.7759/cureus.86368 · Cited by 1
How to Leverage Implementation Science to Achieve Equity in Nephrology Care Delivery
Reddy, Y. N. V., Ashcraft, L. E., & Mendu, M. L. (2025) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2025.03.029 · Cited by 1
Sind GLP-1-Rezeptor-Agonisten und SGLT2-Inhibitoren auch im höheren Lebensalter geeignet?
Stüdemann, S., & Engeli, S. (2025) · Diabetes aktuell · doi:10.1055/a-2588-6338
Kommentar zu „SGLT2-Inhibitoren und Nierenfunktion“
Alscher, M. D. (2025) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2546-0726
В поисках новых методов нефропротективной терапии при синдроме Альпорта
Евгеньевна, А. М. (2025) · Педиатрия Восточная Европа · doi:10.34883/pi.2025.13.2.011
SGLT2 Inhibitors: Increasing Benefits, Continued Concerns
Hernandez-Morgan, M., Disque, A. A., & Neelankavil, J. P. (2025) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2025.06.052
SGLT2-Hemmung bei Patienten mit Diabetes mellitus Typ 1 und CKD
Seidel, M. (2025) · Die Nephrologie · doi:10.1007/s11560-025-00858-y
Bengoa-Urrengoechea, I., Aguilar‐Palacio, I., Rabanaque, M. J., Lallana, M. J., Cabezas, A. G., & Malo, S. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1530139
The kidney as sensitive marker of disease severity in cardiogenic shock after myocardial infarction
Damman, K., Legtenberg, S., & ter Maaten, J. M. (2025) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuaf095
Cho, S., Mak, J., Udell, J. A., Gold, W. L., & Weisman, A. (2025) · Canadian Medical Association Journal · doi:10.1503/cmaj.241400-f
Gerdes, C., & Wolf, G. (2025) · Nephrologie aktuell · doi:10.1055/a-2536-2689
Chen, K., Du, Y., & Zhu, Y. (2025) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-025-00840-9 · Cited by 1
Effects of Combination Treatment on Renal Endothelial Function in Type 2 Diabetes Mellitus
Günes-Altan, M., Bosch, A., Striepe, K., Schiffer, M., Schmieder, R. E., & Kannenkeril, D. (2025) · Kidney International Reports · doi:10.1016/j.ekir.2025.07.023 · Cited by 1
The Portuguese Albuminuria Study: national insights into prevalence and risk factors
Ferreira, A. C., Farinha, A., & Almeida, E. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf240
“Portugal has the highest rate of dialysis patients in Europe and ranks eighth globally [2 , 3 ], underscoring the urgent need for effective and proactive interventions [4 –6 ].”
Organ-protective antidiabetic prescriptions in type 2 diabetes – a single institution experience
Siderova, M. V., Shopov, G., Kehayova, G. K., & Dragomanova, S. (2025) · Pharmacia · doi:10.3897/pharmacia.72.e163319
Lederer, E. D. (2025) · Nephrology Self-Assessment Program · doi:10.58483/nsap.00382025
Uric Acid Nephropathy and Gout
Jayanti, S., & Bose, B. (2025) · Nephrology Self-Assessment Program · doi:10.58483/nsap.00192025
Lido, P., Lullo, L. D., Infante, M., Ricordi, C., Rezk, S., Romanello, D., D’Urso, G., Ceravolo, M. J., Della‐Morte, D., Tesauro, M., et al. (2025) · Current Medical Research and Opinion · doi:10.1080/03007995.2025.2544594 · Cited by 1
Adipositas und Herz: neue Medikamente und neue Strategien für Kardiologen
Hollstein, T. (2025) · Aktuelle Kardiologie · doi:10.1055/a-2606-7020
Empagliflozin – Langzeiteffekte bei chronischer Nierenkrankheit
Scherrer, P., Nitschmann, S., & Müller, R. (2025) · Die Innere Medizin · doi:10.1007/s00108-025-01963-9
The synergistic treatment of heart and kidney disease
Mahfoud, F., Götzinger, F., Kramann, R., Marx, N., & Schwenger, V. (2026) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2025.0131 · Cited by 1
Novel therapies – IMID Co-morbidities
Lam, T. T., So, H., & Tam, L. (2025) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2025.102089
Campos, C., King, A., Miller, E. M., & Morales, J. (2025) · Clinical Diabetes · doi:10.2337/cd25-0040 · Cited by 1
Emphasis on Cardio-Renal-Metabolic Syndrome: Early Risk Assessment and Integrated Management
拉迪力江·努尔合买提, 木. (2025) · Medical Diagnosis · doi:10.12677/md.2025.154059
Integrating and Simplifying Evidence to Optimize Cardiorenal Guideline-Directed Therapies
Singh, H., Puckett, C., & Lucas, Y. Q. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14165883
“Similarly, the Study of Heart and Kidney Protection with Empagliflozin (EMPA-KIDNEY) [63] showed renoprotective effects across a broad range of patients at risk for CKD progression.”
Expanding the therapeutic frontier: esaxerenone in hypertensive patients with CKD and albuminuria
Kanasaki, K. (2025) · Hypertension Research · doi:10.1038/s41440-025-02313-w
Regulatorik: neue Endpunkte in chronische Nierenerkrankungs(CKD)-Studien
Kronbichler, A., & Ksiazek, S. H. (2025) · Die Nephrologie · doi:10.1007/s11560-025-00874-y
Pedicino, D., & Volpe, M. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf568
郝, 升. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.1582412
NEFROPATIA DIABÉTICA: DA AVALIAÇÃO CLÍNICA AO TRATAMENTO MEDICAMENTOSO E COMPORTAMENTAL
da Cunha, G. N. M. A., Chiaradia, N. B. F., Vidigal, C. S., et al. (2025) · Revista Foco · doi:10.54751/revistafoco.v18n8-132
Yan, T.-C., Chua, H., Khatri, P., Rastogi, S., Koh, S., Ma, V., & Ngoh, C. (2025) · Journal of Primary Care & Community Health · doi:10.1177/21501319251365314
“18,19,21 Regulatory approvals followed, with the U.S. Food and Drug Administration endorsing cana-gliflozin, dapagliflozin, and empagliflozin for CKD patients between 2020 and 2023.”
Efficacy of dapagliflozin on uric acid in patients with moderate-to-severe chronic kidney disease
Yanai, K., Hirai, K., Kitano, T., Miyazawa, H., Ito, K., Ookawara, S., & Morishita, Y. (2025) · Clinical and Experimental Nephrology · doi:10.1007/s10157-025-02766-w
“…part of clinical practice guidelines to slow the progression of chronic kidney disease (CKD) in patients with and without diabetes mellitus [3–5], because SGLT-2 inhibitors inhibit the decline in renal function in patients with CKD. [6, 7] Therefore, many patients with CKD take SGLT-2 inhibitors.”
Evolution of Views on Pathogenesis and Treatment of Immunoglobulin A-Nephropathy: What’s New Today?
Николаевна, С. О., Ефремова, Е. В., Богданова, А. Р., & Хасанова, М. И. (2025) · The Russian Archives of Internal Medicine · doi:10.20514/2226-6704-2025-15-5-325-335
Kosaki, K., Mori, S., Namatame, H., Kobayashi, R., Yoshikoshi, S., Tarumi, T., Usui, T., Saito, C., Gosho, M., Nakata, Y., et al. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04471-y
Rhee, C. M., Allon, M., & Mehrotra, R. (2025) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000898
Rhee, C. M., Allon, M., & Mehrotra, R. (2025) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000906
Rhee, C. M., Allon, M., & Mehrotra, R. (2025) · Kidney360 · doi:10.34067/kid.0000001005
Patient education and monitoring of sodium-glucose co-transporter 2 inhibitors in diabetes
Pignatelli-Ruiz, M., & Hill, M. (2025) · Practice Nursing · doi:10.12968/pnur.2025.0043
Management von osteologischen und renalen Komorbiditäten bei rheumatologischen Erkrankungen
Schatz, A., Xanthouli, P., Triantafyllias, K., et al. (2025) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-025-01724-x
Doumani, G., Theofilis, P., Vordoni, A., Smirloglou, D., & Kalaitzidis, R. (2025) · Minerva Medica · doi:10.23736/s0026-4806.25.09747-2
Metadata
- Authors
- The EMPA-KIDNEY Collaborative Group
- Corresponding author
- The EMPA-KIDNEY Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-01-12
- Volume
- 388
- Issue
- 2
- Pages
- 117-127
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7614055
- OpenAlex
- W4308183941
- Cited by
- 2,754
- References
- 26
- Citations by year
- 2026: 727 · 2025: 759 · 2024: 734 · 2023: 520
- FWCI
- 321.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by-nd)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Docusalut (Conselleria de Salut i Consum del Govern de les Illes Balears) (submittedVersion, cc-by-nd)
- Hispana (submittedVersion, cc-by-nd)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Bristol Research (University of Bristol) (submittedVersion)
- Explore Bristol Research (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Funders
- Boehringer Ingelheim
- Eli Lilly and Company
- NIHR Biomedical Centre, Oxford
- Health Data Research
- Medical Research Council (MC_UU_00017/3 & MR/R007764/1)
- Kidney Research UK (MR/R007764/1)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- empagliflozin, chronic kidney disease, kidney disease progression, cardiovascular mortality, heart failure hospitalization, SGLT2 inhibitors, EMPA-KIDNEY trial, estimated glomerular filtration rate, diabetes mellitus
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Cardiovascular Diseases, Creatinine, Diabetes Mellitus, Type 2, Glomerular Filtration Rate, Glucosides, Humans, Kidney, Disease Progression, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.